<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346086</url>
  </required_header>
  <id_info>
    <org_study_id>AAC01-03-27-01</org_study_id>
    <secondary_id>NRH01</secondary_id>
    <nct_id>NCT00346086</nct_id>
  </id_info>
  <brief_title>DNA Vaccine for Ragweed Allergic Adults</brief_title>
  <official_title>A Phase II Observer-blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety, Tolerability, and Immunogenicity of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults (Sponsor's Protocol NRH01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      Various chemical modifications of allergens have been attempted to enhance efficacy, improve&#xD;
      safety, and foster compliance with IT. These approaches have been unsuccessful - in that the&#xD;
      allergenicity and immunogenicity have either decreased, or increased in tandem, with no&#xD;
      resultant efficacy: safety benefit ratio. This study utilizes an adjuvant approach in which&#xD;
      synthetic immunostimulatory DNA is conjugated to ragweed allergen in an attempt to modulate&#xD;
      both the clinical and immunologic allergic response to ragweed exposure in ragweed-allergic&#xD;
      patients with seasonal rhinitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of efficacy and safety of allergen-CpG oligonucleotide immunostimulatory conjugate&#xD;
      in treatment of ragweed-induced seasonal allergic rhinitis. Study incorporates clinical&#xD;
      outcomes (symptom diaries, medication diaries, visual analog scores, quality of life&#xD;
      questionnaires), safety measurements, immunologic assays (antibody measurements, T-cell&#xD;
      assays, cytokine assays, nasal provocation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2001</start_date>
  <completion_date type="Actual">August 21, 2001</completion_date>
  <primary_completion_date type="Actual">August 21, 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of treatment on nasal allergen challenge</measure>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIC (Amb a 1 Immunostimulatory Conjugate)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men and women 18 to 60 years of age;&#xD;
&#xD;
          -  Who provide informed consent;&#xD;
&#xD;
          -  Have a history of fall, seasonal, allergic rhinitis consistent with ragweed allergy;&#xD;
&#xD;
          -  Exhibit a positive skin test to licensed , standardized, ragweed extract and a&#xD;
             positive acute response to ragweed nasal challenge;&#xD;
&#xD;
          -  Are in general good health; and are available for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with medical conditions or taking medications that might interfere with&#xD;
             interpretation of the study results will be excluded.&#xD;
&#xD;
          -  Those with a history of severe symptoms of allergic rhinitis during the spring and&#xD;
             summer grass pollen season will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter S Creticos, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 27, 2006</study_first_submitted>
  <study_first_submitted_qc>June 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2006</study_first_posted>
  <last_update_submitted>December 12, 2018</last_update_submitted>
  <last_update_submitted_qc>December 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CpG oligonucleotide vaccine</keyword>
  <keyword>ragweed immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

